A "shot heard 'round the world" on cancer drug costs?

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 10, Issue 11, 2012, Pages 1315-1316

  Burstein, Harold J ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; OXALIPLATIN;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; DRUG APPROVAL; DRUG COST; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MECHANISM; EDITORIAL; HEALTH CARE ORGANIZATION; HUMAN; PRACTICE GUIDELINE; PRESCRIPTION;

EID: 84871409734     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2012.0136     Document Type: Editorial

References (2)

1. Bach PB, Saltz LS, Wittes RE. In cancer care, cost matters. New York Times 2012:October 14.
2. Benson AB III, Bekaii-Saab T, Chan E, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Colon Cancer. Version 1.2013. Available at NCCN.org. Last accessed October 22, 2012.